Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma

Blood

Volumn 101, Issue 4, 2003, Pages 1487-1493

  Kleinhans, Martin ^b   Tun Kyi, Adrian ^b   Gilliet, Michel ^b   Kadin, Marshall E ^b   Dummer, Reinhard ^b   Burg, Günter ^b   Nestle, Frank O ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR8; GAMMA INTERFERON; INTERLEUKIN 4; LIGAND; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES;

ACTIN POLYMERIZATION; ARTICLE; CELL SUSPENSION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; LYMPHOMA CELL; MONOCYTE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; TH2 CELL;

EID: 0037441761     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0475     Document Type: Article

References (48)

1. Longo DL. Lymphomas: complexity, not chaos. Curr Opin Oncol. 2000;12:379-382.
2. Burg G, Dummer R, Nestle FO, Doebbeling U, Haeffner A. Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Arch Dermatol. 1996;132:567-572.
3. Jaffe ES, Sander CA, Flaig MJ. Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L./WHO Classification. Ann Oncol. 2000;11(suppl 1):17-21.
4. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354-371.
5. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653-3661.
6. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14:219-228.
7. Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, Butcher EC. Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma. Am J Pathol. 1988;130:496-504.
8. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66.
9. Nickoloff BJ, Griffiths CE, Baadsgaard O, et al. Markedly diminished epidermal keratinocyte expression of intercellular adhesion molecule-1 (ICAM-1) in Sézary syndrome. JAMA. 1989;261:2217-2221.
10. Hwang ST, Fitzhugh DJ. Aberrant expression of adhesion molecules by Sézary cells: functional consequences under physiologic shear stress conditions. J Invest Dermatol. 2001;116:466-470.
11. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593-620.
12. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
13. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000;95:627-632.
14. Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96:685-690.
15. McCluggage WG, Walsh MY, Bharucha H. Anaplastic large cell malignant lymphoma with extensive eosinophilic or neutrophilic infiltration. Histopathology. 1998;32:110-115.
16. Nickoloff BJ. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol. 1988;10:469-477.
17. Luster AD, Rothenberg ME. Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. J Leukoc Biol. 1997;62:620-633.
18. Nestle FO, Burg G, Fah J, Wrone-Smith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 1997;150:641-651.
19. Bleul CC, Fuhlbridge RC, Casanovas JM, Aiuti A, Springer TA. A highly efficient lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184:1101-1109.
20. Davis TH, Morton CC, Miller-Cassman R, Balk SP, Kadin ME. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med. 1992;326:1115-1122.
21. Petering H, Kluthe C, Dulkys Y, et al. Characterization of the cc chemokine receptor 3 on human keratinocytes. J Invest Dermatol. 2001;116:549-555.
22. Amara A, Gall SL, Schwartz O, et al. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med. 1997;186:139-146.
23. Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392:565-568.
24. Yagi H, Tokura Y, Furukawa F, Takigawa M. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma. J Invest Dermatol. 1996;107:827-832.
25. Burg G, Braun-Falco O. Cutaneous Lymphomas, Pseudolymphomas and Related Disorders. Berlin, Germany: Springer: 1983.
26. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28:973-980.
27. Feller AC, Sterry W. Large cell anaplastic lymphoma of the skin. Br J Dermatol. 1989;121:593-602.
28. Kadin ME. Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann Oncol. 1994;5:25-30.
29. Kadin ME. Anaplastic large cell lymphoma and its morphological variants. Cancer Surv. 1997;30:77-86.
30. Stein H, Gerdes J, Kirchner H, et al. Immunohistological analysis of Hodgkin's and Sternberg-Reed cells: detection of a new antigen and evidence for selective IgG uptake in the absence of B cell, T cell and histiocytic markers. J Cancer Res Clin Oncol. 1981;101:125-134.
31. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299:65-67.
32. von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med. 2000;343:1020-1034.
33. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187:875-883.
34. Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Th1 lymphocytes. Nature. 1998;391:344-345.
35. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129-134.
36. Gerber BO, Zanni MP, Uguccioni M, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol. 1997;7:836-843.
37. Siveke JT, Hamann A. T helper 1 and T helper 2 cells respond differentially to chemokines. J Immunol. 1998;160:550-554.
38. Ponath PD, Qin S, Post TW, et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively, on'eosinophils. J Exp Med. 1996;183:2437-2448.
39. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol. 1994;103:669-673.
40. Dummer R, Heald PW, Nestle FO, et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996;88:1383-1389.
41. Vermeer MH, Tensen CP, van der Stoop PM, et al. Absence of TH2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. Arch Dermatol. 2001;137:901-905.
42. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001;2:108-115.
43. Buri C, Korner M, Scharli P, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood. 2001;97:1543-1548.
44. Petering H, Hochstetter R, Kimmig D, et al. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol. 1998;160:555-558.
45. Bartels J, Schluter C, Richter E, et al. Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression, and identification of eotaxin sequence variants. Biochem Biophys Res Commun. 1996;225:1045-1051.
46. Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood. 2001;97:1920-1924.
47. Tensen CP, Vermeer MH, van der Stoop PM, et al. Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J Invest Dermatol. 1998;111:222-226.
48. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.